Dermatology

Shingles (Herpes Zoster): Drug Therapy

Therapeutic targets Shortening the symptomatic phase Avoidance of complications Therapy recommendations Antiviral therapy: as soon as possible: virostasis (antivirals/drugs that inhibit viral replication)Note: Antiviral therapy within 72 hours of vesicle breakdown also reduces the risk of postzoster neuralgia.First-line therapy: Patients <50 years + limited findings on trunk and extremities: Antivirals (aciclovir, brivudine, valaciclovir, and famciclovir), … Shingles (Herpes Zoster): Drug Therapy

Shingles (Herpes Zoster): Diagnostic Tests

Diagnosis is usually made on the basis of history and physical examination. Optional medical device diagnostics – depending on the results of the history, physical examination, laboratory diagnostics, and obligatory medical device diagnostics – for differential diagnosis in case of complications. Computed tomography of the skull (cranial CT, cranial CT or cCT) – if meningoencephalitis … Shingles (Herpes Zoster): Diagnostic Tests

Polymorphous Light Dermatosis: Drug Therapy

Therapeutic target Alleviation of symptoms Therapy recommendations Beta-carotene Nicotinamide and folic acid Corticosteroids; azathioprine in extreme individual cases. Antihistamines can relieve the itching See also under “Further therapy“. All agents have in common a relatively limited efficacy. In experimental studies, efficacy has been demonstrated for E. coli extract. Supplements (dietary supplements; vital substances) Appropriate dietary … Polymorphous Light Dermatosis: Drug Therapy

Shingles (Herpes Zoster): Symptoms, Complaints, Signs

The following symptoms and complaints may indicate herpes zoster (shingles): Prodromal stage (early phase of disease in which nonspecific symptoms occur; about 5 days): First, nonspecific general symptoms (fatigue, impaired performance, fever, and aching limbs) occur. Then local pruritus (itching) and paresthesias (sensory disturbances). Then appearance of typical zoster vesicles (herpetiform vesicles; centrally forked, usually … Shingles (Herpes Zoster): Symptoms, Complaints, Signs

Polymorphous Light Dermatosis: Prevention

Limiting sun exposure contributes to the prevention of polymorphous light dermatosis. Prophylaxis is of significant importance. By becoming accustomed to light by means of, for example, phototherapy to general light protection measures (sunscreens with a high sun protection factor (UV-A and UV-B protection), the wearing of caps/hats, etc.), the affected person can prevent or reduce … Polymorphous Light Dermatosis: Prevention

Shingles (Herpes Zoster): Causes

Pathogenesis (development of disease) Herpes zoster is a reactivation of the varicella zoster virus (synonyms: varicella zoster virus (VZV) – also spelled varicella zoster virus and referred to as human herpes virus-3), which has survived inconspicuously for many years in the area of the spinal and/or cranial nerve ganglia. Due to a weakened immune system, … Shingles (Herpes Zoster): Causes

Polymorphous Light Dermatosis: Symptoms, Complaints, Signs

The following symptoms and complaints may indicate polymorphous light dermatosis: Initially, itching occurs, followed by patchy redness of the skin. Thereafter, the following efflorescences (skin changes; skin bloom) may occur: Bullae (blisters) Papules (vesicles) Papulo-vesicle – a mixture of papule and vesicle (vesicle) represents. Plaques (areal or plate-like substance proliferation of the skin). Predilection sites … Polymorphous Light Dermatosis: Symptoms, Complaints, Signs

Polymorphous Light Dermatosis: Causes

Pathogenesis (disease development) The exact cause of polymorphous light dermatosis is not known. In recent studies, it is thought that immune regulation is disrupted after UV exposure. About 75% of affected individuals have exclusive UV-A sensitivity. 15% show UV-A/B sensitivity. It has been observed that polymorphous light dermatosis also occurs from sun exposure behind window … Polymorphous Light Dermatosis: Causes

Polymorphous Light Dermatosis: Therapy

General measures Prophylactic measures (staged scheme according to progression): Light acclimation in spring/summer (about 75% of affected individuals have exclusive UV-A sensitivity, 15% show UV-A/B sensitivity). Sunscreen with broad-spectrum effect and sun protection factor 30-50 with the addition of antioxidants. In acute polymorphous light dermatosis: Sunscreen External (external) anti-inflammatory (anti-inflammatory) measures, corticosteroid creams if necessary. … Polymorphous Light Dermatosis: Therapy